pibozobactam

Pibozobactam (XNW4107) is a novel, broad-spectrum diazabicyclooctane (DBO) beta-lactamase inhibitor (BLI) designed to restore the activity of carbapenems against multi-drug resistant (MDR) Gram-negative bacteria. It features a unique spiro-cyclopropane modification to the DBO core and an oxadiazole-linked cyclic guanidine moiety, which enhances its potency and spectrum of activity. Pibozobactam effectively inhibits serine beta-lactamases across Ambler Classes A (e.g., KPC), C (e.g., AmpC), and D (e.g., OXA-23, OXA-48), making it particularly effective against resistant strains of *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and Enterobacterales. Developed by Evopoint Biosciences and Xuanzhu Biopharmaceutical, pibozobactam is primarily being evaluated in combination with imipenem and cilastatin for the treatment of severe infections, including hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).

Other names

(1r,4s)-4-(5-((s)-2-iminioimidazolidin-4-yl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1'-cyclopropan]-7-yl sulfate(1R,2S,5R)-2-{5-[(4S)-2-amino-4,5-dihydro-1H-imidazol-4-yl]-1,3,4-oxadiazol-2-yl}-7-oxo-1,6-diazaspiro[bicyclo[3.2.1]octane-4,1'-cyclopropan]-6-yl hydrogen sulfate